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Context: In persons with impaired glucose tolerance (IGT), both impaired insulin secretion and
insulin resistance contribute to the conversion to type 2 diabetes mellitus (T2DM). However, few
studies have used criterion standard measures to asses the predictive value of impaired insulin
secretion and insulin resistance for the conversion to T2DM in a Caucasian IGT population.
Objectives: The objective of the studywas to determine the predictive value ofmeasures of insulin
secretion and insulin resistance derived from a hyperglycemic clamp, including the disposition
index, for the development of T2DM in a Caucasian IGT population.
Design, Setting, and Participants: The population-based Hoorn IGT study consisted of 101 Dutch
IGT subjects (aged  75 yr), with mean 2-h plasma glucose values, of two separate oral glucose
tolerance tests,between8.6and11.1mmol/liter.Ahyperglycemic clampatbaselinewasperformed
to assess first-phase and second-phase insulin secretion and insulin sensitivity. During follow-up,
conversion to T2DM was assessed by means of 6-monthly fasting glucose levels and yearly oral
glucose tolerance tests.
Results: The cumulative incidence of T2DM was 34.7%. Hazard ratio for T2DM development ad-
justed for age, sex, and body mass index was 5.74 [95% confidence interval (CI) 2.60–12.67] for
absence of first insulin peak, 1.58 (95% CI 0.60–4.17) for lowest vs. highest tertile of insulin sen-
sitivity, and 1.78 (95% CI 0.65–4.88) for lowest vs. highest tertile of the disposition index.
Conclusions: In these Caucasian persons with IGT, the absence of the first insulin peak was the
strongest predictor of T2DM. (J Clin Endocrinol Metab 93: 2633–2638, 2008)
Impaired glucose tolerance (IGT) is a strong risk factor fordeveloping type2diabetesmellitus (T2DM).Aboutone third
of people with IGT develops T2DM in 5–10 yr time (1, 2). The
general idea is that insulin resistance precedes -cell dysfunction
in the process of conversion to T2DM (3–7). Most evidence for
the predictive value of insulin resistance and -cell function for
T2DM was based on estimates derived from oral glucose toler-
ance tests (OGTTs), like fasting and 2-h postload insulin levels,
fasting proinsulin levels, and the ratio between fasting proinsulin
and fasting insulin levels.However, the agreement between these
estimates and the criterion standards for insulin sensitivity and
-cell function are far fromperfect (8, 9). The criterion standards
for assessing -cell function and insulin sensitivity are, respec-
tively, the first (and second) insulin secretion phase of the hy-
perglycemic clamp and the M-value of the euglycemic hyperin-
sulinemic clamp (10).
Because of the strong correlation between the M-value to
insulin (M/I) ratio of the hyperglycemic clamp and the M-value
(10–12), the M/I ratio can also be used to assess insulin sensi-
tivity. Clamp studies are time consuming, invasive, and labor
intensive and therefore difficult to use in large epidemiological
studies. Therefore, only few clamp studies have been performed.
Only in populationswith a high risk for developing T2DM, such
as in Pima Indians, or in populations with IGT, have iv glucose
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tolerance tests or clamp tests been used (6, 7, 13, 14). In these
studies, the first insulin secretion phase was the strongest pre-
dictor fordevelopingT2DM(3).However, insulin resistanceand
-cell function have a close interrelationship, and this has not
been taken into account in most of these studies. In general,
insulin resistance is compensated for by an increase in insulin
secretion (15). Thus, high insulin productionmay be regarded as
good -cell function, whereas in reality the insulin production
may already be impaired (16, 17). This compensatory insulin
secretion in the presence of insulin resistance is taken into ac-
count in the disposition index, the product of insulin sensitivity,
and insulin secretion. In this study, we analyzed the predictive
value of measures, derived from a hyperglycemic clamp, of in-
sulin resistance and insulin secretion, including the disposition
index, for the development of T2DM in a Caucasian IGT
population.
Subjects and Methods
Study population
The participants in our analysis came from two existing studies.
The population-based cohort Hoorn Study, conducted in
1989–1991, analyzed the glucose metabolism of 2484 men and
women of the municipality of Hoorn (18). During the 1996–1998
follow-up, we identified 55 patients with IGT, all of whomwere under
75 yr of age and had mean fasting plasma glucose levels of 6–7 mmol/
liter and mean 2-h postload plasma glucose levels of 7.8–11.1 mmol/
liter. For the Dutch Acarbose Intervention Study in IGT Persons
(DAISI) study, conducted in 1994–1995, a random sample of 12,093
men andwomenwas also taken from the population register ofHoorn
(19). From that sample, 6651 participants underwent two OGTTs
within 2 wk. Of those, we included the 108 participants who were
under 70 yr of age and had mean fasting plasma glucose levels of
5.5–7.8 and mean 2-h postload plasma glucose levels of 8.6–11.1
mmol/liter. The coefficient of variation was 6.5% for fasting plasma
glucose and 16.7% for 2-h postload plasma glucose (18). These 108
persons together with the 55 IGT persons from the Hoorn study (n
163) were randomized in the DAISI study (19). The intervention
group (acarbose, n  54) was excluded from the present analysis.
Finally, the study population for the present analysis consisted of 109
subjects.
All participants signed written informed consents, and the study was
approvedby theEthicalReviewCommitteeof theVUUniversityMedical
Center.
Measurements
OGTT
Blood samples were taken from all patients in a fasting state and 2 h
after a 75-g oral glucose load. We used a glucose hexokinase-method
(Roche Diagnostics GmbH, Mannheim, Germany) to determine fasting
and 2-h postload plasma glucose levels. We determined insulin levels
using a two-site immunoradiometric test (Medgenix Diagnostics, Fleu-
rus, Belgium). This insulin-specific test does not show cross-reactivity
with proinsulin and split products. Intact proinsulin was determined by
immunoradiometric method based on antibodies (Dako, Cam-
bridgeshire, UK).
Hyperglycemic clamp
Participants underwent a hyperglycemic clamp after at least 12 h of
fasting. Lying supine, patients received a priming infusion of saline
(0.9%) and glucose (20%) in one arm. To sample blood, we cannulated
a vein on the back of the hand of the opposite arm. The hand was placed
in a thermo-regulated box at 45 C to arterialize the venous blood. After
infusing the patients with a bolus of glucose (150 mg/kg), we took im-
mediate blood glucose measurements every 2.5 min with a glucose an-
alyzer (Yellow Springs Instrument, Inc., Yellow Springs, OH); we main-
tained blood glucose levels at a hyperglycemic level of 10 mmol/liter for
180 min. We obtained insulin samples every 2.5 min during the first 10
min and at 5- to 10-min intervals for the remaining 170 min.
Clamp-derived estimates of insulin sensitivity
Under stable conditions of constant hyperglycemia, the amount of
glucose infused (milligrams per kilogram per minute) equals the amount
ofmetabolized glucose. The amount of glucose infusedwas calculated by
the areaunder the curveof the glucose infusion rateduring the last 20min
of the clamp using the trapezoidal rule. The M value divided by the
average plasma insulin concentration during the same interval, the M/I
ratio, provides a measurement of tissue sensitivity to insulin (milligrams
per kilogram per minute per milliunit per liter).
Clamp-derived estimates of -cell function
Several measures of -cell function were obtained from the hyper-
glycemic clamp (20). The first insulin secretion phase was assessed in the
first 15 min of the clamp. For the definition of the presence of a first
insulin peak, we used the following procedure. By visual inspection, we
selected 23 flat insulin curves. For each separate curve, we calculated the
SD of the insulin values.Next, from these 23 SDs,we calculated the pooled
estimate of the typical SD of these flat curves. We considered an insulin
peak present if the difference between two subsequent insulin levels ex-
ceeded 1.962 pooled estimate (Fig. 1).
Another measure for the first insulin secretion phase was the area
under the curve (AUCins0–10) of the insulin levels of the first 10min of the
clamp, which were calculated using the trapezoidal rule. The second
insulin secretion phase (160–180 min) was calculated by the mean in-
sulin level of that period (ins160–180).
Other measurements
During the baseline medical examination, we measured weight, height,
andwaist and hip circumferences and calculated bodymass index (BMI)
and waist to hip ratio. We measured blood pressure twice on the right
arm with a random-zero sphygmomanometer (Hawksley-Gelman Ltd.,
Lancing, UK) and used the mean in our analyses.
Disposition index
The disposition index was calculated as the product of M/I ratio
(micrograms per kilogram per minute per milliunits per liter) and the
AUCins0–10 (milliunits per liter).
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FIG. 1. Difference between persons with and without a peak of insulin
levels in the first 15 min of the hyperglycemic clamp.
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Conversion to diabetes
When the study started, theWorldHealthOrganization (WHO) had
in 1985 defined T2DM as a fasting plasma glucose value of 7.8 mmol/
liter or greater and/or a 2-h plasma glucose value of 11.1 mmol/liter or
greater (21). In 1999, during the study, the WHO lowered the fasting
plasma glucose value criterion to 7.0 or greater (the 2 h plasma glucose
value remained  11.1 mmol/liter) (22). We used both sets of WHO
criteria in separate analyses (not allWHO1985 analyses are shown). For
the analysis with the WHO 1999 criteria, participants with a fasting
plasma glucose of 7.0 mmol/liter or greater at the start of the study were
excluded.
In the participants of the DAISI study, fasting plasma glucose levels
were measured every 3 months for 3 yr and once a year thereafter. In the
participants of the Hoorn Study, fasting plasma glucose was measured
yearly. Participants underwent an OGTT if the fasting plasma glucose
level reachedavalueof6.0mmol/literor greateror at the endof the study.
For subjects not developing T2DM, the follow-up timewas calculated as
years from the date of the baseline clamp to the end of the study, with a
maximum of 8 yr.
Statistical methods
Quantitative data are expressed as means with SDs (skewed variables
as medians with interquartile ranges) and categorical data as percent-
ages. ANOVA was performed to test for statistically significant differ-
ences between continuous variables, the skewed variableswere log trans-
formed first. When variances were unequal among the groups to test
(Levene’s test), differences were evaluated by Mann-Whitney U test. 2
test was used to test for categorical variables. We calculated the cumu-
lative incidence ofT2DMusing the 1999WHOdefinition.The incidence
was also calculated in tertiles of the clamp-derived measures of insulin
resistance and-cell function and in tertiles of thedisposition index, after
which Kaplan-Meier survival curves were plotted.Multivariate analyses
were performed, adjusted for sex and age, using Cox proportional haz-
ard analysis. Insulin resistance and -cell function were first analyzed
separately and subsequently combined in one model. The relative risk of
the incidence of T2DM was calculated as a hazard ratio with a 95%
confidence interval. All statistical analyses were performed with SPSS
12.0.1 (SPSS Inc., Chicago, IL). P  0.05 was considered to be statisti-
cally significant.
Results
The cumulative incidence of T2DM according to 1999 WHO
criteria was 34.7% (mean follow-up 4.2 yr; range 0.5–8.0 yr).
Table 1 presents the baseline characteristics for participantswho
did and did not develop T2DM.
Themean glucose level during the clampwas 10.2mmol/liter
(SD 1.07), the coefficient of variation of the glucose level during
the clamp was 10,5%. The mean glucose level during the last 20
min of the clamp was 9.9 (SD 0.6), the coefficient of variation
6.6%.
Figure 2 showsKaplan-Meier survival curves for the presence
or absence of the first insulin peak and tertiles of the M/I ratio,
disposition index, and first insulin secretion phase. The absence
of the first insulin peak was the strongest predictor for the de-
velopment of T2DM.
Table 2 shows the results of Cox proportional hazards
analyses ofOGTTand clamp-derivedmeasures for the incidence
ofT2DMforboth the1985and1999WHOcriteria, adjusted for
age, sex, and BMI. The highest hazard ratiowas observed for the
absence of the first insulin peak. The other variables were not as
predictive of T2DM development (1999 WHO criteria). First-
phase insulin secretion, insulin resistance, second-phase insulin
secretion, and the disposition index were not significantly asso-
ciated with the risk of developing T2DM. When we applied the
WHO 1985 criteria, however, the first insulin secretion phase
and the disposition index were both predictive of T2DM
conversion.
TABLE 1. Baseline characteristics of participants developing and not developing diabetes
1999 WHO definition
No diabetes
Mean (SD)
Diabetes
Mean (SD) P value
n 66 35
Age (yr) 62.7 (8.9) 61.3 (9.1) 0.45
Sex (percent men) 50% 40% 0.23
Hemgolobin A1c 5.5 (0.5) 5.7 (0.6) 0.10
BMI (kg/m2) 27.3 (3.7) 29.0 (4.4) 0.04
Waist
Women 92.2 (84.3–97.6) 98.0 (88.6–102.3) 0.14
Men 95.4 (92.0–99.0) 99.4 (95.7–106.3) 0.06
Waist to hip ratio
Women 0.88 (0.80–0.95) 0.90 (0.80–0.92) 0.19
Men 0.94 (0.80–1.00) 0.90 (0.90–0.95) 0.43
OGTT measurements
Fasting plasma glucose (mmol/liter) 5.9 (0.7) 6.5 (0.6) 0.001
Two-hour postload plasma glucose (mmol/liter) 7.8 (2.0) 9.3 (1.1) 0.001
Fasting specific insulin (mU/liter) 9.0 (7.2–12.3) 11.4 (8.5–15.8) 0.04
Fasting proinsulin (mU/liter) 2.3 (1.8–3.0) 2.8 (2.1–5.3) 0.06
Hyperglycemic clamp measurements
Peak (percent present) 80% 52% 0.004
AUC, 0–10 min (mU/liter min1) 24.6 (16.7–34.1) 21.9 (15.4–39.4) 0.95
Mean insulin, 160–180 min (mU/liter min1) 48.1 (36.1–78.8) 47.9 (33.4–103.6) 0.75
MI ratio (mg/kg/min per mU/1) 11.2 (6.3–15.2) 9.8 (4.4–16.2) 0.29
Disposition index 226.4 (147.5–349.9) 176.8 (137.4–307.6) 0.14
Values are means (SD) or medians (interquartile ranges) for skewed variables.
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Additional analyses in the eight persons with T2DM accord-
ing to the WHO 1999 criteria, thus excluded at baseline,
demonstrated that their fasting and 2-h plasma glucose values
were higher at baseline than in those who developed T2DM at
the follow-up (Table 3). They were younger and the percentage
of women was higher among these eight persons than in the
group of new T2DM. They also had a higher percentage of ab-
sence of first-insulin peak and a lower mean disposition index.
Discussion
The incidence of T2DM in this confirmed IGT population was
almost 35%, with a relatively short mean follow-up period of 4
yr. The absence of the first insulin peak was the strongest pre-
dictor of the development of T2DM. The second insulin secre-
tion phase, insulin resistance, and the disposition index did not
independently predict T2DM.
The participants were selected according to the 1985 WHO
criteria, but during the study the WHO criteria for T2DM
changed. For the 1999 WHO analyses, therefore, we excluded
participants with a fasting plasma glucose greater than 7.0
mmol/liter. The true criterion standard measurement for insulin
sensitivity is the M-value of the hyperinsulinemic euglycemic
clamp (22, 23). Because, the M-value of the hyperinsulinemic
clamp and the M/I value of the hyperglycemic clamp are highly
correlated (11, 12), a hyperglycemic clampwas themost efficient
way to analyze both insulin resistance and -cell function. We
observed that AUCins0–10 as a measure of first-phase insulin se-
cretion did not predict the conversion to T2DM. Probably this
can be explained by the close relationship between the AUCins0–
10, themeasure of insulin sensitivity. In our data AUCins0–10 was
strongly correlated with the M/I ratio derived from the hyper-
glycemic clamp (data not shown). Perhaps unexpected, insulin
resistance did not emerge as a significant independent predictor
of diabetes. This is likely to be due to the fact all participants had
FIG. 2. Kaplan-Meier survival curves for either the presence of a first insulin secretion peak (A), insulin sensitivity (B), the disposition index (C), and first-
phase insulin secretion (D).
2636 Nijpels et al. Insulin Secretion in Impaired Glucose Tolerance J Clin Endocrinol Metab, July 2008, 93(7):2633–2638
IGT, itself an insulin-resistant state. Also, previous studies have
demonstrated that insulin resistance is a predictor of conversion
only in persons with normal glucose tolerance at baseline (3, 4).
In persons with an adequate -cell function, the AUC0–10
will be higher in insulin-resistant persons, compared with per-
sons with a normal insulin sensitivity. The resulting disposi-
tion index and glucose tolerance will remain the same. In
contrast, those who are not able to increase the (first) phase
insulin secretion in response to insulin resistance, thus those
with an absent first phase, will develop hyperglycemia. Insulin
resistance itself stimulates insulin secretion, an adaptation of
the -cell for prevailing insulin resistance (26, 27). The dis-
position index, reflects the interrelationship between insulin
secretion and insulin resistance. Alterations in the disposition
index has been demonstrated to be predictive of changes in
glucose tolerance status as reported by others (7, 19, 26–28).
This study is one of the few prospective studies with measure-
ments of the first insulin secretion phase in confirmed IGT
persons and the first to report prospective analyses with the
disposition index in aCaucasian IGTpopulation (8). Impaired
first insulin secretion phase as an independent predictor for
the development of T2DM, independent of obesity and insulin
resistance, has also been described in a population in Sweden,
in Pima Indians (29–34), and in Mexican-Americans (3). We
found that the incidence of T2DM was predicted best by the
absence of the peak of the first insulin secretion phase. In the
prospective study in Pima Indians, the findings were very
similar, although their estimate of -cell function was ac-
quired with an iv glucose tolerance test (38).
The disposition index, as an expression of the compensa-
tory mechanism of insulin secretion on decreasing insulin
sensitivity, appeared to be an independent predictor of
the incidence of T2DM but only when we used the old
WHO 1985 criteria. This is line with the notion that elevated
fasting glucose (7.0–7.8 mmol/liter) clearly indicates defec-
tive insulin secretion and that fasting glucose levels less than
7.0 mmol/liter indicates sufficient compensatory insulin se-
cretion (22).
In summary, the present study of Caucasian patients fol-
lowed up prospectively over several years showed that the
TABLE 3. Comparison of the excluded T2DM (WHO, 1999) at baseline with the new T2DM at the follow-up
Variables T2DM excluded T2DM follow-up
n 8 35
Age 57.8 (6.9) 63.0 (8.8)
Sex (percent male) 37.0 45.0
BMI 30.7 (3.2) 28.6 (4.5)
Fasting plasma glucose (mmol/liter) 7.3 (0.2) 6.5 (0.6)
Two-hour postload plasma glucose (mmol/liter) 9.7 (0.6) 9.3 (1.1)
Peak (percent present) 37.5 52.0
Disposition index 128.4 (66.3–259.4) 176.8 (137.4–307.6)
M/I ratio 8.1 (2.5–18.1) 7.1 (3.8–10.0)
Values are means (SD) or medians (interquartile ranges) for skewed variables.
TABLE 2. Cox proportional hazard analyses for diabetes, all models adjusted for age, sex, and BMI
Model
WHO, 1985
Hazard ratio (95% CI)
WHO, 1999
Hazard ratio (95% CI)
Absence of insulin peak
Model 1 6.47 (2.76–15.19)a 5.74 (2.60–12.67)a
Model 2 7.26 (2.97–17.75)a 5.68 (2.55–12.64)a
AUC0–10 (model 1)
Tertile 1 vs. tertile 3 2.09 (0.78–5.70) 0.71 (0.26–1.93)
Tertile 2 vs. tertile 3 1.29 (0.46–3.61) 0.71 (0.30–1.69)
AUC0–10 (model 2)
Tertile 1 vs. tertile 3 4.10 (1.22–13.80)b 0.86 (0.29–2.57)
Tertile 2 vs. tertile 3 1.53 (0.54–4.30) 0.75 (0.25–1.67)
Ins160–180 (model 1)
Tertile 1 vs. tertile 3 1.05 (0.41–2.73) 0.64 (0.25–1.67)
Tertile 2 vs. tertile 3 0.80 (0.30–2.13) 0.72 (0.30–1.71)
M/I ratio (model 1)
Tertile 1 vs. tertile 3 1.68 (0.55–5.10) 1.58 (0.60–4.17)
Tertile 2 vs. tertile 3 1.62 (0.52–5.06) 0.96 (0.34–2.70)
DI (model 1)
Tertile 1 vs. tertile 3 4.95 (1.38–17.77)b 1.78 (0.65–4.88)
Tertile 2 vs. tertile 3 1.72 (0.43–6.85) 1.20 (0.44–3.24)
Cox regression models, all adjusted for age, sex, and BMI (model 1) and age, sex, BMI, and insulin sensitivity (model 2). CI, Confidence interval; Ins160–180, mean insulin
level between 160 and 180 min of the hyperglycemic clamp; DI, disposition index.
a P  0.001.
b P  0.01.
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absence of the first insulin peak, as an expression of an im-
paired acute insulin response to glucose, was the strongest
predictor of incident T2DM.
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